These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 9769784

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA.
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [Abstract] [Full Text] [Related]

  • 5. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994 Jul; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 6. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G, Milani A, Piva L, Faustini M, Spino E.
    Eur Urol; 1991 Apr 15; 20(2):89-92. PubMed ID: 1752280
    [Abstract] [Full Text] [Related]

  • 9. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S, Kubota Y, Shuin T, Hosaka M, Miura T, Kondoh I.
    Int J Urol; 1994 Jun 15; 1(2):140-2. PubMed ID: 7543010
    [Abstract] [Full Text] [Related]

  • 10. [Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
    Nakagawa S, Nakao M, Toyoda K, Nukui M, Takada H, Ebisui K, Watanabe H, Kobayashi T, Maegawa M.
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep 15; 79(9):1510-5. PubMed ID: 3244217
    [No Abstract] [Full Text] [Related]

  • 11. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y.
    J Clin Oncol; 1993 Mar 15; 11(3):408-14. PubMed ID: 7680373
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb 15; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug 15; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump D.
    J Clin Oncol; 1997 Jul 15; 15(7):2564-9. PubMed ID: 9215826
    [Abstract] [Full Text] [Related]

  • 17. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ.
    J Clin Oncol; 2002 Mar 01; 20(5):1361-7. PubMed ID: 11870180
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN, de Mulder PH, van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR.
    Ann Oncol; 1993 May 01; 4(5):403-7. PubMed ID: 8353075
    [Abstract] [Full Text] [Related]

  • 20. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 01; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.